liver, biliary and pancreatic tumors
Conditions
Interventions
Sponsors
Sichuan Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Patients with liver cancer: Age greater than 18 years old;clinically diagnosed with any grade of early or intermediate-stage liver cancer through histological and/or tumor marker tests. 2. Patients with cholangiocarcinoma: Age greater than 18 years old; diagnosed with any grade of early or intermediate-stage cholangiocarcinoma through histological and/or cytological tests. 3. Patients with pancreatic cancer: Age greater than 18 years old; diagnosed with pancreatic cancer through pathological examination or considered as pancreatic cancer through imaging tests. 4. Healthy individuals: Age greater than 30 years old;without any tumors or suspected nodules through systematic examinations; identified as healthy individuals through systematic examinations and without other major chronic diseases.
Exclusion criteria
Exclusion criteria: 1. Poor health condition or unsuitable for blood sampling; 2. Female subjects who are pregnant or breastfeeding; 3. Those diagnosed with tumors other than bile duct cancer or with a previous history of tumors; 4. Subjects who have received any form of tumor treatment before blood sampling, including surgery, radiotherapy/chemotherapy, targeted therapy and immunotherapy; 5. Those who have received blood transfusion within 7 days before blood collection; 6. Organ transplant recipients or those who have received non-autologous (allogeneic) bone marrow or stem cell transplantation previously; 7. Individuals with febrile diseases, or those who have experienced acute attacks or inflammatory disease flares within 14 days before blood sampling and are undergoing medical treatment; 8. Subjects considered by the investigators to potentially affect adherence to the protocol, or affect the signing of informed consent forms, or are not suitable for participating in this clinical trial, including any other clinically significant diseases or conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cfDNA fragmentomic features; | — |
Secondary
| Measure | Time frame |
|---|---|
| sensitivity;specificity; | — |
Countries
China
Contacts
Public ContactYu Zhou
Sichuan Provincial People's Hospital
Outcome results
None listed